Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of Perspective Therapeutics in a research report issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($1.20) for the year, down from their prior forecast of ($1.19). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share.
Other analysts have also issued reports about the stock. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target on the stock. Bank of America lowered Perspective Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Wedbush reiterated an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Finally, Brookline Capital Management raised Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Perspective Therapeutics currently has an average rating of "Buy" and a consensus price target of $14.56.
View Our Latest Analysis on CATX
Perspective Therapeutics Trading Down 2.0 %
Shares of Perspective Therapeutics stock traded down $0.05 during midday trading on Friday, hitting $2.47. The company had a trading volume of 246,214 shares, compared to its average volume of 992,000. Perspective Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.05. The business's 50 day simple moving average is $3.00 and its two-hundred day simple moving average is $6.57.
Institutional Investors Weigh In On Perspective Therapeutics
A number of hedge funds have recently made changes to their positions in CATX. Charles Schwab Investment Management Inc. grew its stake in Perspective Therapeutics by 221.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company's stock worth $5,788,000 after buying an additional 298,778 shares during the last quarter. State Street Corp grew its position in Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company's stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Perspective Therapeutics by 8.0% during the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company's stock valued at $64,014,000 after purchasing an additional 355,685 shares in the last quarter. FMR LLC increased its holdings in Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company's stock valued at $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in Perspective Therapeutics by 1,302.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company's stock valued at $635,000 after purchasing an additional 44,174 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company's stock.
Perspective Therapeutics Company Profile
(
Get Free Report)
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Featured Articles

Before you consider Perspective Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list.
While Perspective Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.